ABSTRACT
OBJECTIVE: Epilepsy is a suitable target for gene panel sequencing because a considerable portion of epilepsy is now explained by genetic components, especially in syndromic cases. However, previous gene panel studies on epilepsy have mostly focused on pediatric patients. METHODS: We enrolled adult epilepsy patients meeting any of the following criteria: family history of epilepsy, seizure onset age ≤ 19 years, neuronal migration disorder, and seizure freedom not achieved by dual anti-seizure medications. We sequenced the exonic regions of 211 epilepsy genes in these patients. To confirm the pathogenicity of a novel MTOR truncating variant, we electroporated vectors with different MTOR variants into developing mouse brains. RESULTS: A total of 92 probands and 4 affected relatives were tested, and the proportion of intellectual disability (ID) and/or developmental disability (DD) was 21.7%. As a result, twelve probands (13.0%) had pathogenic or likely pathogenic variants in the following genes or regions: DEPDC5, 15q12-q13 duplication (n = 2), SLC6A1, SYNGAP1, EEF1A2, LGI1, MTOR, KCNQ2, MEF2C, and TSC1 (n = 1). We confirmed the functional impact of a novel truncating mutation in the MTOR gene (c.7570C > T, p.Gln2524Ter) that disrupted neuronal migration in a mouse model. The diagnostic yield was higher in patients with ID/DD or childhood-onset seizures. We also identified additional candidate variants in 20 patients that could be reassessed by further studies. SIGNIFICANCE: Our findings underscore the clinical utility of gene panel sequencing in adult epilepsy patients suspected of having genetic etiology, especially those with ID/DD or early-onset seizures. Gene panel sequencing could not only lead to genetic diagnosis in a substantial portion of adult epilepsy patients but also inform more precise therapeutic decisions based on their genetic background. PLAIN LANGUAGE SUMMARY: This study demonstrated the effectiveness of gene panel sequencing in adults with epilepsy, revealing pathogenic or likely pathogenic variants in 13.0% of patients. Higher diagnostic yields were observed in those with neurodevelopmental disorders or childhood-onset seizures. Additionally, we have shown that expanding genetic studies into adult patients would uncover new types of pathogenic variants for epilepsy, contributing to the advancement of precision medicine for individuals with epilepsy. In conclusion, our results highlight the practical value of employing gene panel sequencing in adult epilepsy patients, particularly when genetic etiology is clinically suspected.
Subject(s)
Epilepsy , Humans , Adult , Epilepsy/genetics , Male , Female , Mice , Animals , TOR Serine-Threonine Kinases/genetics , Young Adult , Adolescent , Middle Aged , Mutation , Intellectual Disability/genetics , Genetic TestingABSTRACT
BACKGROUND: Neurodegeneration with brain iron accumulation describes a group of rare heterogeneous progressive neurodegenerative disorders characterized by excessive iron accumulation in the basal ganglia region. Pantothenate kinase-associated neurodegeneration (PKAN) is a major form of this disease. RESULTS: A total of 7 unrelated patients were diagnosed with PKAN in a single tertiary center from August 2009 to February 2018. Ten variants in PANK2 including three novel sequence variants and one large exonic deletion were detected. Sequencing of the breakpoint was performed to predict the mechanism of large deletion and AluSx3 and AluSz6 were found with approximately 97.3% sequence homology. CONCLUSION: The findings support the disease-causing role of PANK2 and indicate the possibility that exonic deletion of PANK2 found in PKAN is mediated through Alu-mediated homologous recombination.
Subject(s)
Mutation , Pantothenate Kinase-Associated Neurodegeneration , Humans , Iron/metabolism , Pantothenate Kinase-Associated Neurodegeneration/genetics , Pantothenate Kinase-Associated Neurodegeneration/metabolism , Phosphotransferases (Alcohol Group Acceptor)/genetics , Phosphotransferases (Alcohol Group Acceptor)/metabolismABSTRACT
In spite of favourable hydrogen storage properties such as low density, high theoretical capacity (7.6 wt% H/MgH2) and economics, commercial use of Mg-based alloys is not feasible due to long activation times, slow hydrogen sorption kinetics, and a high temperature for hydrogen release. Mg- Ni alloys have been considered promising materials for hydrogen storage systems as the Mg2Ni intermetallic phase enhances the kinetics of hydrogen absorption in Mg-Ni alloys through a catalytic effect. It has been suggested that the refinement of eutectic in Mg-Ni alloys can further improve hydrogen absorption kinetics and that this can be achieved through trace Na additions. However, the refinement of the eutectic can also be achieved by increasing the cooling rate during solidification. In this study we investigate the effect of cooling rate and Na additions to Mg-Ni alloys on hydrogen absorption kinetics. Our results indicate that Na additions improve the hydrogen absorption kinetics independent of eutectic refinement and that the effect of the latter is relatively small.
ABSTRACT
The ability to control the dimensions and properties of nanomaterials is fundamental to the creation of new functions and improvement of their performances in the applications of interest. Herein, we report a strategy based on glucan multivalent interactions for the simultaneous exfoliation and functionalization of two-dimensional transition metal dichalcogenides (TMDs) in an aqueous solution. The multivalent hydrogen bonding of dextran with bulk TMDs (WS2, WSe2, and MoSe2) in liquid exfoliation effectively produces TMD monolayers with binding multivalency for pathogenic bacteria. Density functional theory simulation reveals that the multivalent hydrogen bonding between dextran and TMD monolayers is very strong and thermodynamically favored (ΔEb = -0.52 eV). The resulting dextran/TMD hybrids (dex-TMDs) exhibit a stronger affinity (Kd = 11 nM) to Escherichia coli O157:H7 (E. coli) than E. coli-specific antibodies and aptamers. The dex-TMDs can effectively detect a single copy of E. coli based on their Raman signal.
Subject(s)
Biosensing Techniques , Chalcogens/chemistry , Coordination Complexes/chemistry , Dextrans/chemistry , Escherichia coli O157/isolation & purification , Nanostructures/chemistry , Antibodies , Hydrogen Bonding , Molybdenum/chemistry , Nanostructures/ultrastructure , Quantum Theory , Sensitivity and Specificity , Spectrum Analysis, Raman , Thermodynamics , Tungsten/chemistry , Water/chemistryABSTRACT
Modulating the dimensions and phases of transition metal dichalcogenides is of great interest to enhance their intrinsic properties or to create new physicochemical properties. Herein, we report an effective approach to synthesize 2H-WS2 quantum dots (QDs) via the dimension and phase engineering of 1T-WS2 nanosheets. The solvothermal reaction of chemically exfoliated 1T-WS2 nanosheets in N-methyl-2-pyrrolidone (NMP) under an N2 atmosphere induced their chopping and phase transition at lower temperature to produce 2H-WS2 QDs with a high quantum yield (5.5 ± 0.3%). Interestingly, this chopping and phase transition process showed strong dependency on solvent; WS2 QDs were not produced in other solvents such as 1,4-dioxane and dimethyl sulfoxide. Mechanistic investigations suggested that NMP radicals played a crucial role in the effective production of 2H-WS2 QDs from 1T-WS2 nanosheets. WS2 QDs were successfully applied for the selective, sensitive, and rapid detection of dopamine in human serum (4 min, as low as 23.8 nM). The intense fluorescence of WS2 QDs was selectively quenched upon the addition of dopamine and Au3+ ions due to fluorescence resonance energy transfer between WS2 QDs and the quickly formed Au nanoparticles. This new sensing principle enabled us to discriminate dopamine from dopamine-derivative neurotransmitters including epinephrine and norepinephrine, as well as other interference compounds.
Subject(s)
Quantum Dots , Fluorescence Resonance Energy Transfer , Humans , Neurotransmitter AgentsABSTRACT
It has been of great interest to measure the activity of acetylcholinesterase (AChE) and its inhibitor, as AChE is known to accelerate the aggregation of the amyloid beta peptides that underlie Alzheimer's disease. Herein, we report the development of graphene oxide (GO) fluorescence-based biosensors for the detection of AChE activity and AChE inhibitors. To this end, GO was non-covalently functionalized with phenoxy-modified dextran (PhO-dex-GO) through hydrophobic interaction; the resulting GO showed excellent colloidal stability and intense fluorescence in various aqueous solutions as compared to pristine GO and the GO covalently functionalized with dextran. The fluorescence of PhO-dex-GO remarkably increased as AChE catalyzed the hydrolysis of acetylthiocholine (ATCh) to give thiocholine and acetic acid. It was found that the turn-on fluorescence response of PhO-dex-GO to AChE activity was induced by protonation of carboxyl groups on it from the product of the enzymatic hydrolysis reaction, acetic acid. On the basis of its turn-on fluorescence response, PhO-dex-GO was able to report kinetic and thermodynamic parameters involving a maximum velocity, a Michaelis constant, and an inhibition dissociation constant for AChE activity and inhibition. These parameters enable us to determine the activity of AChE and the efficiency of the inhibitor.
Subject(s)
Acetylcholinesterase/chemistry , Amyloid beta-Peptides , Biosensing Techniques , Graphite , Acetylthiocholine , Cholinesterase Inhibitors , OxidesABSTRACT
We evaluated the performance of solid oxide fuel cells (SOFCs) with a 50 nm thin silver (Ag) cathode surface treated with cerium oxide (CeO(x)) by atomic layer deposition (ALD). The performances of bare and ALD-treated Ag cathodes were evaluated on gadolinia-doped ceria (GDC) electrolyte supporting cells with a platinum (Pt) anode over 300 °C-450 °C. Our work confirms that ALD CeO(x) treatment enhances cathodic performance and thermal stability of the Ag cathode. The performance difference between cells using a Ag cathode optimally treated with an ALD CeO(x) surface and a reference Pt cathode is about 50% at 450 °C in terms of fuel cell power output in our experiment. The bare Ag cathode completely agglomerated into islands during fuel cell operation at 450 °C, while the ALD CeO(x) treatment effectively protects the porosity of the cathode. We also discuss the long-term stability of ALD CeO(x)-treated Ag cathodes related to the microstructure of the layers.